

## Assessment of the Opacity of Titanium Dioxide Free Film Coating Formulations

Alyson Hui Ling Tee<sup>a\*</sup>, Michaela Ogden-Barker<sup>a</sup>, Kieran Sproston<sup>a</sup>

<sup>a</sup>Drug Product Design, Pfizer R&D, Sandwich, Kent, United Kingdom.

### ARTICLE INFO

Received: 02/06/2023  
Accepted: 08/07/2023  
Published: 30/12/2023

\*Corresponding author.  
E-mail:  
huiling.tee@pfizer.com

KEYWORDS: TiO<sub>2</sub>, TiO<sub>2</sub>-free, film coating, Titanium Dioxide, opacity.

### SUMMARY

Titanium dioxide (TiO<sub>2</sub>) is widely used as an excipient in pharmaceutical film coating formulations. In August 2022, the European commission (EC) adopted a ban on the use of TiO<sub>2</sub> (E171) as a food additive. There is uncertainty around the implications of this decision on pharmaceutical products, and a potential need to find suitable alternatives to TiO<sub>2</sub>. In this study, we evaluated the opacity of the different TF film coating systems by assessing the ability of TF film coatings to mask coloured tablet cores at varying weight gains. HPMC-based film coatings containing CaCO<sub>3</sub> demonstrated the best covering potential and were positively correlated to the amount of CaCO<sub>3</sub> present, while PVA-based film coatings containing CaCO<sub>3</sub> showed poor coverage, even at 9% weight gain.

© BY 4.0 Open Access 2023 – University of Huddersfield Press

### INTRODUCTION

Titanium dioxide (TiO<sub>2</sub>) is widely used as an excipient in pharmaceutical film coating formulations. TiO<sub>2</sub> acts as a colourant, opacifier and protection from UV light due to its high refractive index and light-scattering properties (Hughes, 2022). In August 2022, the European commission (EC) adopted a ban on the use of TiO<sub>2</sub> (E171) as a food additive (European Medicines Agency, 2021). This created uncertainty around the use of TiO<sub>2</sub> in pharmaceuticals, and potential need to find suitable TiO<sub>2</sub> alternatives with comparable opacity, whiteness, chemical inertness, and photoprotection to satisfy the replacement requirements.

In this study, we evaluate the opacity of the different TiO<sub>2</sub>-free (TF) film coatings by assessing the ability of TF film coatings to mask coloured tablet cores at varying film coating weight gains, providing its aesthetics.

### MATERIALS AND METHODS

**Table 1.** Photographs of white-coated tablets using different TF film coatings at increasing weight gains.

Coating name	Opacifiers and their quantity in film coating (%)	Pictures/Target weight gain(%)					
		0	1	3	5	7	9
TI	TiO <sub>2</sub> : 25						
C38	CaCO <sub>3</sub> : 38						
CM1	CaSO <sub>4</sub> , MgCO <sub>3</sub>						
CI	CaCO <sub>3</sub> : 35, Isomalt: 30						
CM2	CaCO <sub>3</sub> : 27, MgCO <sub>3</sub> : 25						
C35	CaCO <sub>3</sub> : 35						
RI	Rice starch: 35, Isomalt: 30						
CRI	CaCO <sub>3</sub> : 25, Rice starch: 10, Isomalt: 10						
ZT	ZnO: 25, Talc: 10						
CP2	CaCO <sub>3</sub> : 45						
CP1	CaCO <sub>3</sub> : 25						

Ten TF film coating systems with different TiO<sub>2</sub> opacifier alternatives (CaCO<sub>3</sub>, Rice starch, MgCO<sub>3</sub>, ZnO, CaSO<sub>4</sub>) were selected to coat black placebo

tablets to assess their ability to mask coloured tablet cores at different coated weight gains (1%, 3%, 5%, 7% and 9%). CP1 and CP2 were PVA-based film-coating formulations while the rest were HPMC-based. TiO<sub>2</sub> - containing film coating acted as the control in this study.

Whiteness assessment was carried out on these film-coated tablets using the ColorFlex® EZ spectrophotometer. The L\*, a\* and b\* values were measured and ΔE was calculated for each weight gain and film coating using the black tablet cores as reference (Fig. 1).

$$\Delta E = \sqrt{(L1 - L2)^2 + (a1 - a2)^2 + (b1 - b2)^2}$$

L1 - the L\* value of reference colour (black tablet)

a1 - the a\* value of reference colour (black tablet)

b1 - the b\* value of reference colour (black tablet)

L2 - the L\* value of sample colour

a2 - the a\* value of sample colour

b2 - the b\* value of sample colour

Fig. 1. Equation for ΔE.

## RESULTS AND DISCUSSION

The ΔE values for each film coating at different weight gains are shown in Fig. 2. The higher the ΔE value, the easier it is for the human eye to perceive the colour difference between two samples. Human eye perception test is ongoing to understand the significance of ΔE values.




Fig. 2. ΔE values calculated with respect to the black tablet cores as reference at different weight gains

HPMC-based film coatings containing CaCO<sub>3</sub> demonstrated the best covering potential and were positively correlated to the amount of CaCO<sub>3</sub> present.

This was followed by the TF film-coating containing both CaSO<sub>4</sub> and MgCO<sub>3</sub>. However, these TF film coatings still required a weight gain of ≥7% to achieve similar coverage to TiO<sub>2</sub> at the standard 3% weight gain. In contrast, rice starch with isomalt did not show comparable whiteness to TiO<sub>2</sub>. ZnO was initially thought to be the most promising alternative to TiO<sub>2</sub> due to its similarity in particle size (Radtke et al., 2021), however it did not exhibit good covering potential. ZnO may still possess good opacifying properties in terms of photostability, investigation into this is currently ongoing. Lastly, PVA-based film coatings containing CaCO<sub>3</sub> showed poor coverage, even at 9% weight gain.

## CONCLUSIONS

In conclusion, HPMC-based TF film-coating formulations containing CaCO<sub>3</sub> provided the best covering potential. These were positively correlated to the amount of CaCO<sub>3</sub> present in the film coatings. PVA-based formulations containing CaCO<sub>3</sub> exhibited poor covering potential, even at 9% weight gain. Further studies assessing the ability of TF coating systems to protect against photodegradation are ongoing.

## ACKNOWLEDGEMENTS

Thank you to the team in the Drug Product Design Department at Pfizer for their contributions.

## REFERENCES

- European Medicines Agency, 2021. Final feedback from European Medicine Agency (EMA) to the EU Commission request to evaluate the impact of the removal of titanium dioxide from the list of authorised food additives on medicinal products. Available from: [final-feedback-european-medicine-agency-ema-eu-commission-request-evaluate-impact-removal-titanium\\_en.pdf](https://www.ema.europa.eu/en/documents/other/final-feedback-european-medicine-agency-ema-eu-commission-request-evaluate-impact-removal-titanium_en.pdf) (europa.eu)
- Hughes, K., 2022. Pharmaceutical Excipients: Titanium Dioxide. Medicines Complete. Available from: MedicinesComplete – CONTENT > Pharmaceutical Excipients > Substance: Titanium Dioxide
- Radtke, J., Wiedey, R., Kleinebudde, P., 2021. Alternatives to titanium dioxide in tablet coating. Pharmaceutical Development and Technology, 26(9), 989-999. doi: 10.1080/10837450.2021.1968900.